move bench bedsid evolut
near clinic inflect point initi buy
initi coverag buy rate price
biolog drug research develop compani
expertis protein engin current near valu
inflect point number clinic catalyst buy thesi base
upon three key point optimist use
treatment system lupu erythematosu sle upcom
phase read-out first clinic data
could help valid emerg
pipelin commerci partner asset
help support cash flow next sever year
optimist read-out phase sle studi
clear risk head phase
read-out combin preced in-
human clinic data sle sle studi signific rate
failur given variabl diseas activ combin background
therapi said think drug activ autoimmun
disord novel trial design provid basi optim
forecast potenti sle approv commerci launch
first clinic data could help
valid emerg immune-oncolog pipelin xencor
bispecif antibodi one lead next-
gener immunotherapi candid first clinic data
program expect base upon clinic data
flotetuzumab gener optimist
data readout model revenu split
novarti us equat sale
commerci partner asset
help support cash flow next sever year although
receiv modest royalti either effort emerg
dataset look posit support
net royalti commerci sale
valuat pt valu ev sale
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
move bench bedsid evolut
initi coverag buy rate price
biolog drug research develop compani
expertis protein engin current near valu inflect point
number clinic catalyst buy thesi base upon three key
point optimist use treatment
system lupu erythematosu sle upcom phase read-out
first clinic data could help
valid emerg immune-oncolog pipelin commerci
partner asset help support cash flow
next sever year price base upon stock trade
ev sale estim
optimist read-out phase sle studi
clear risk head phase read-out
combin preced in-human clinic data
sle sle studi signific rate failur given variabl
diseas activ combin background therapi said least
phase studi test rheumatoid arthriti
patient read-out rd provid view vivo clinic
activ novel trial design sle studi could provid
favor hurdl success overal model success sle effort
potenti approv commerci launch
first clinic data could help valid
bispecif antibodi one lead next-gener immunotherapi
drug candid develop engag cell
arm aml blast arm first
clinic data program expect base upon
corollari clinic data effort flotetuzumab
gener optimist outlook financi
project model split revenu novarti within
us equat drug sale
commerci partner asset help
support cash flow next sever year although receiv
modest royalti either effort emerg dataset
look posit support net royalti revenu
commerci sale
figur share outperform nbi index past
forward price valu share ev/
sale forecast figur view premium valuat
reason compar peer compani within xncr smid-cap biotech
group carri median ev/ revenu multipl sinc
expect earli phase growth furthermor view financi
estim conserv current thesi prove correct compani
deep pipelin wholli own immune-oncolog asset reach clinic
stage next year
figur price valu share ev/ sale forecast
debt equivel
number import stock catalyst cours
compani approach clinic inflect point
updat phase sle studi phase sle
studi expect posit result key compon
sale forecast util treatment sle contribut
current sale forecast drug
first clinic data expect
xencor bispecif antibodi one lead
next-gener immunotherapi drug candid develop
compani engag cell arm aml
blast arm think dataset could help
valid emerg immune-oncolog pipelin
top-line result phase dose escal studi
updat on-going studi
bispecif program also major catalyst data posit
market opportun could substanti sinc signific
improv clinic standard neuroendocrin gist octreotid
regulatori file iv dose pnh ahu
like alexion rate proceed
regulatori file pnh eu japan data
phase ahu studi forthcom sbla
follow manag also plan initi subcutan trial
pivot l-mind studi result expect data
support l-mind studi evalu line dlbcl expect
updat plan develop
expect data third phase trial studi
idelalisib expect european hematolog associ
annual meet june
drugind lupu erythematosusupd on-going phase clinic trial diseaseiniti phase trial myeloid leukemia updat first-in phase result gi stromal tumorsupd on-going phase dose escal studi malignanciesupd first-in phase result ind applic data updat phase studi clinic mid ico oncolog ind applic paroxysm nocturn hemoglobinuriaregulatori fill phn larg b-cell lymphomadata pivot l-mind studi line dlbcl expect
near term anchor valuat
sle read-out catalyst
xencor
clinic
develop expect read-out top-line result on-going
system lupu erythematosu sle phase studi
expect present acr base upon compar result
approv sle drug benlysta along current compendium
pre-clin clinic data think good
basi expect posit result phase sle studi
posit data phase sle studi key compon sale
forecast util treatment sle contribut
current sale forecast drug figur also
import compani
on-track subcutan
formul key driver benlysta commerci growth
view phase dataset present
american colleg rheumatolog novemb highli
encourag phase registr studi expect begin
howev current estim phase studi
run therefor expect addit us data
program sever year
origin partner rate
regain full develop right compound
first-in-human clinic studi rheumatoid arthriti ra
origin agreement base upon regain control
decid focu sle versu continu develop
within ra display clear clinic activ within part
dataset look like compel step ahead anti-tnf agent
figur forecast sale reach
result phase studi safeti tolerabili pharmacokinet pharmacodynam patient rheumatoid
arthriti ra zack foster et al acr/arhp annual meet
sle accommod trial design
state expect releas data phase studi
system lupu erythematosu sle
may coincid annual american colleg rheumatolog acr
confer may press releas clear risk head
phase read-out combin preced in-
human clinic data sle sle studi signific rate failur
given variabl diseas activ combin background therapi
said least phase studi test
rheumatoid arthriti patient studi provid view vivo
clinic activ novel trial design sle studi could support
favor hurdl success
system lupu erythematosu sle multi-organ auto-immun disord
defin in-part presenc antidouble-strand dna antibodi
result global failur self-toler clinic manifest divers
core demograph women around age child-bear therapeut
intervent gener use resolv flare diseas activ sustain
remiss vari organ involv approxim patient
diagnos sle experi chronic diseas and/or frequent flare
significantli impact qualiti life product patient
musculoskelet involv unabl work nephriti
kidney involv risk end stage renal estim
individu direct cost impact sle rang annual
unit state
current backbon therapi sever set corticosteroid
prednisolon cytotox agent cyclophosphamid
cytoxan supplant variou immuno-suppress agent
hydroxychloroqui methotrex mycophenol mofetil
benlysta current approv b-cell target agent gain
util sinc sub-cutan formul approv
rituximab continu evalu b-cell target agent use remain
off-label major pivot trial lunar explor fail
differenti steroid immunosuppress agent
emerg role b-cell target therapi sle
approv benlysta belimumab b-cell target therapi
treatment systemat lupu erythematosu sle first us fda
approv new therapi treat sle sinc approv plaquenil
benlysta gener annual sale signific growth
attribut addit sub-cutan dose option
addit origin intra-ven formul figur despit effort
develop rituximab use sle one wide use b-cell
target therapi across autoimmun disord oncolog pivot studi
achiev posit clinic result support regulatori approv
belimumab system lupu erythematosu hahn engl april
said rituximab use off-label treatment sle util
rate rang patient across major european
figur benlysta gener sale sle
benlysta succeed rituximab fail like due better design
pivot studi bliss studi use sle
respond index primari endpoint incorpor composit
selena-sledai reduct bilag new bilag
one new bilag pga deterior baselin least
point visual analog scale score bliss
studi achiev statist signific kg dosag belimumab
plu standard versu control arm placebo plu standard
figur record respons rate versu
placebo week studi record
respons rate versu placebo week
extent pattern off-label use rituximab sle sanz rheumatol novemb
measur diseas activ adult system lupu erythematosu challeng administr burden respons
patient concern clinic research mikdashi nive arthriti ther
belimumab system lupu erythematosu sle evidence-to-d clinic use castro isenberg therapeut advanc
figur result pivot studi belimumab sle
belimumab system lupu erythematosu hahn engl april
despit success bliss studi subsequ us fda ema
approv efficaci belimumab remain question around slow onset
action patient respond first discontinu
due advers event achiev neither respons advers effect
also remain question around steroid spare effect belimumab
bliss studi display limit differ versu placebo prednison
mechan action moa belimumab offer biolog explan
efficacy/tox balanc drug fulli human
mab bind solubl bli inhibit receptor bind activ
moa pursu result find signific percentag
sle patient elev plasma level solubl bli growth
factor requir b-cell develop activ howev memori b-cell
lack b-cell activ factor baff bind receptor bli thu
render memori b-cell unrespons effect spare
memori b-cell like reduc induct effect belimumab treatment
also reduc risk opportunist infect retent protect
regard current clinic treatment algorithm sle foremost issu
concern clinician current depend steroid beyond
extens side-effect associ long-term use glucocorticosteroid
accrual organ damag attribut steroid util document
sever long-term studi steroid also specif link
increas mortal risk associ slicc/ acr damag
belimumab system lupu erythematosu hahn engl april
use rituximab newli diagnos patietn system lupu erythematosu long-term steroid save capac clinic
effect gracia-tello isenberg et al lupu scienc medicin
outcom week phase trial belimumabplacebobelimumabp valuerespons studi medic flare dose reduc mg/day level posit neg anti-dsdna antibodi assay immunoglobulin level increas short-form survey rang higher score indic better health-rel qualiti life
steroid-spar concept key foundat block explor b-cell
target therapi continu spawn interest rituximab sinc despit
failur larg studi explor studi found
signific benefit reduct steroid util rituximab part
treatment algorithm figur
figur rituximab b-cell target agent found significantli reduc steroid util
use rituximab newli diagnos patietn system lupu erythematosu long-term steroid save capac clinic
effect gracia-tello isenberg et al lupu scienc medicin
unfortun steroid-spar accept regulatori endpoint
sle studi evidenc explor studi outcom figur
immunosuppress agent difficult without accommod studi
respons beyond standard
figur rituximab fail differenti soc placebo explor studi
efficaci safeti rituximab moderately-to-sever active system lupu erythematosu random double-blind
phase ii/iii system lupu erythematosu evalu rituximab trial merril brunetta et al arthriti rheum januari
although clinic respons rituximab fail differenti within
explor studi result indic sle popul b-cell
target therapi gener well toler figur
figur rituximab gener well toler sle patient compar soc placebo
discontinu due teae
efficaci safeti rituximab moderately-to-sever active system lupu erythematosu random double-blind
phase ii/iii system lupu erythematosu evalu rituximab trial merril brunetta et al arthriti rheum januari
rational posit outcom phase studi
treatment sle
result phase studi treatment patient
sle expect like top-lin press releas event
one biggest clinic mileston outcom
studi key part invest thesi next
gener posit expect data set sle base
upon trial design cross comparison rituximab ra
valid activ mechan action support pre-
clinic data sle
invert trial design phase studi support clinic signal
mainten remiss approach phase studi design
provid cleaner signal experiment differenti
placebo/soc versu histor respons rate studi
gener plagu develop effort rituximab oppos
histor studi comparison respons experiment
arm control arm phase studi enrol patient meet criteria
diseas control evalu versu alon
immunosuppress therapi exclud arm figur
figur design phase sle studi
think elimin background immunosuppress
dose period chang calculu favor
arm expect result increas rate flare within
steroid monotherapi arm use methotrex background
immunosuppress drug may less current clinic practic sle rel
azathioprin mycophenalt mofetil figur drug
still
substanti use use guid remov
background immunosuppress drug may impact diseas control sle
patient baselin steroid
figur methotrex less popular versu agent still wide use
efficaci safeti rituximab moderately-to-sever active system lupu erythematosu random double-blind
phase ii/iii system lupu erythematosu evalu rituximab trial merril brunetta et al arthriti rheum januari
clinic studi methotrex shown statist
signific impact dosag prednison use methotrex
support lower mean dose prednison figur although specif
impact methotrex diseas activ score mix trend posit
across metric shown statist signific
sensit measur slam-r
figur methotrex use posit impact diseas activ lower prednison util
steroid-spar effect methotrex system lupu erythematosu double-blind random placebo-control trial
zummer et al arthriti rheumat decemb volume
characterist explor studyplacebo durat prednison prednison dosag screen immunosuppress index score entri score score during-tri differencep outcomelog prednison dose mean rel differ daili dose prednison dose baselin vs monthsmethotrex prednison baselin baselin prednison baselin taken decreas baselin
overal success phase studi come balanc
arm control new flare control arm steroid
monotherapi experi loss diseas improv understand
loss improv would like entail elev
sledai score new find use bilag criteria base upon
mechan action coupl clinic experi
background immunosuppress therapi think key compon
phase trial success come expect base event rate diseas
activ within patient popul end clinic experi would
suggest twelve-month period new lupu flare measur
bilag index could experienc caveat
expect would durat studi period
would drop expect flare event rate use continu
probabl assumpt effect baselin stabil steroid
within studi potenti reduc event rate
figur rate lupu flare period use bilag index
definit treatment lupu flare measur bilag index gordon isenberg et al rheumatolog
mainten diseas improv primari outcom phase
studi key clinic aspect studi util steroid
within arm versu control arm steroid monotherapi
steroid spare effect b-cell target agent remain key reason
rituximab continu use off-label explor within treatment
paradigm sle also key reason clinician use benlysta
extent would expect significantli lower util steroid mean
dose across least higher steroid util would
use treatment new flare figur howev key risk
phase studi design relat steroid effect
imbal taper steroid use arm creat higher
event rate would expect rel control arm
definit treatment lupu flare measur bilag index gordon isenberg et al rheumatolog
figur abl differenti steroid util
definit treatment lupu flare measur bilag index gordon isenberg et al rheumatolog
cross comparison rituximab ra help valid
mechan action moa
test clinic outcom phase trial
treatment patient rheumatoid arthriti ra inher limit
abil directli estim clinic effect treatment sle said
robust curriculum rituximab treatment sle
ra allow us compar rituximab ra proxi
effect mechan action despit phase dataset
furthermor direct support evid effect b-cell
target strategi within sle given approv use benlysta benlysta
rituximab differ specif mechan action
share overarch effect downregul b-cell activ figur
treatment advisedpati new bilag score new bilag score prior dose steroid and/ dose chang advisedpati new bilag score new bilag score dose steroid and/ dose chang increas antimalari nsaid anticoagul without chang steroid cytotox agent lupus-rel diseas manifest start increas prednisolon daili equival methylprednisolon dose and/or start increas cytotox agent start increas lower dose prednisolon daili equival steroid intramuscular intra-articular methylprednisolon dose increas antimalari nsaid anticoagul without chang steroid cytotox agent lupus-rel diseas manifest start increas prednisolon daili equival methylprednisolon dose and/or start increas cytotox agent start increas lower dose prednisolon daili equival steroid intramuscular intra-articular methylprednisolon dose
figur compar antibodi design benlysta rituximab
result phase studi treatment ra
incorpor expans cohort kg dose level result
evalu patient popul rel control arm
cours therapi differenti across standard
clinic measur rel placebo arm within kg dose group
figur activ rheumatoid arthriti
phase studi safeti toler pharmacokinet pharmacodynam patient rheumatoid
arthriti jaraczewska-baumann foster et al
mab adcc fc-gamma riibhumanizedyesy fc yesbind targetbaff/ activ nave cell plasma b-cell b-cell inhibitionefficaci assess day diseas
rituximab evalu within numer ra clinic studi use
differ patient popul vari level pre-treat
experi figur compar find averag
rel placebo across rituximab trial in-lin net
respons calcul within studi
figur respons rate rituximab across ra trial
rituximab treatment rheumatoid arthriti updat mok drug design develop therapi
belimumab fail differenti placebo within phase ii random
placebo-control studi rheumatoid arthriti interestingli
patient elev bli level ng/ml respons
differ rel placebo patient low bli level baselin
ng/ml respons belimumab versu placebo
think phenomenon may relat mechan
action belimumab specif bind solubl bli
membran bound bli could limit induct effect
therapeut rel b-cell target agent rel averag
net placebo record across rituximab ra trial phase
ii studi belimumab record respons net placebo week
highest dose level test figur
efficaci safeti belimumab patient rheumatoid arthriti phase ii random double-blind placebo-control
dose-rang studi stohl genoves et al rheumatol
efficaci safeti belimumab patient rheumatoid arthriti phase ii random double-blind pacebo-control dose-
rang studi stohl genoves et al rheumatol
regard safeti highest dosag level use within ra
studi gener well toler figur gastro-intestin
advers event caus patient temporarili suspend infus
experienc hypotens relat infus reaction discontinu
seriou advers event note one relat infus reaction
hypotens deep vein thrombosi event note day
post last infus
across trial rituximab treatment ra infus reaction
experienc patient higher patient infus
relat reaction said infus interrupt
due gi issu notabl although lead
figur well toler dosag level ra patient
phase studi safeti toler pharmacokinet pharmacodynam patient rheumatoid
arthriti jaraczewska-baumann foster et al
broad measur clinic effect b-cell target agent look
compar rituximab differ
mechan action drug could clinic consequ
notabl rituximab antibody-depend cellular cytotox
adcc directli deplet b-cell popul near undetect
contrast inhibitori signal effect drug
induct long-term b-cell deplet refractori rheumatoid arthriti patient preferenti affect autoreact protect
humor immun teng van et al arthriti research therapi
treatment emerg advers upper respiratori relat punctur site pressur temperatur like
reduc activ b-cell popul baselin valu figur
retent endogen b-cell popul help minim risk
opportunist infect leav question regard induction/
mainten effect around auto-immun flare episod said
week data ra look support clinic effect rel
adcc approach rituximab
figur caus reduct activ b-cell popul
phase studi safeti toler pharmacokinet pharmacodynam patient rheumatoid
arthriti jaraczewska-baumann foster et al
preclin data support effect rel rituximab
pre-clin work character demonstr proof-of-concept
co-engag b-cell receptor could suppress b-cell
respons activ fc-gamma riib inhibitori pathway even
condit sle donor b-cell directli stimul
signal factor lp baff significantli inhibit
prolifer cours sever day figur
retain inhibitori effect prolifer even direct
presenc antibodi stimulatori
figur inhibit b-cell prolifer sle donor cell model
antibody-medi coengag fc-gamma riib cell receptor complex suppress humor immun system lupu
erythematosu horton szymkowski et al immunol feb
demonstr compar humor immun suppress
rituximab use scid mice model engraft sle pbmc figur
figur suppress humor immun compar rituximab
antibody-medi coengag fc-gamma riib cell receptor complex suppress humor immun system lupu
erythematosu horton szymkowski et al immunol feb
rel vehicl control significantli prolong surviv
scid mice model engraft sle pbmc figur
figur prolong scid mice engraft sle pbmc rel control
antibody-medi coengag fc-gamma riib cell receptor complex suppress humor immun system lupu
erythematosu horton szymkowski et al immunol feb
diseas repres distant
distinct long-term opportun
lead program diseas rd
current progress pivot studi report
posit data phase studi annual american colleg
rheumatolog acr meet novemb
first
character system condit clinic characterist
diseas tumefact lesion storiform fibrosi elev
concentr found outsid autoimmun pancreat
characterist diseas found manifest across differ
organ system receiv orphan design us fda
may even though expect pivot studi within
us begin model extend enrol timelin
therefor model commerci sale within steroid refractori
popul occur figur despit orphan indic
think total market opportun could within us alon
although current model conserv assumpt
figur forecast launch
epidemiolog studi far limit character
diseas lead frequent diagnosi without monik
result true patient popul difficult estim gener
reli preval estim us provid
said japanes studi seem support incid rate could correl
preval assumpt given diseas high
level associ mortal survey conduct uchida et al
annual incid within japan may
patient per said nationwid survey
uchida okazaki et al survey hospit depart across
japan document case rd includ autoimmun pancreat
diseas sone deshpand et al engl
diseas current challeng futur prospect lang piering et al therapeut clinic risk manag
figur target facil respond calcul
case document case
autoimmun pancreat
figur result nationwid survey preval
given rd newli character diseas current
offici approv drug indic specif said given
physiolog diseas steroid rituximab gener popular choic
patient experi flare patient within
phase studi experi prior therapi treat
prednison treat rituximab figur
figur prednison rituximab commonli use treat rd
phase outcom look promis given patient
complet studi achiev decreas respond
index day figur beyond primari endpoint
patient enter remiss corticosteroid month
importantli corticosteroid taper eventu discontinu
five patient use baselin
base upon outcom phase studi abl type
 end phase meet us fda divis pulmonari allergi
respiratori product dparp agre upon pivot design
phase studi begin pivot design
preval diseas japan base nationwid survey uchida okazaki et al intern journal
stone jh et al final result open label phase studi revers cell inhibitor diseas
patient compar rel standard care therapi
figur respons consist deep within phase studi
result phase studi also strong context
patient enrol studi organ involv median
number organ involv entir popul figur
frequent activ organ baselin patient popul lymph
node patient submandibular gland parotid gland
lacrim gland
figur median number organ involv baselin
compar steroid and/or rituximab dose test
phase studi gener seem well toler figur one notabl
advers event patient test posit anti-drug antibodi
develop rash arthriti infus cycl
figur toler within phase studi look accept
relat possibl probabl definit relat drug per investig
beyond direct clinic data support potenti
treatment found in-vivo pharmacodynam data
help support thesi elicit strong suppress
immun activ without total b-cell deplet experienc
rituximab near complet deplet peripher cell
trough cell count occur baselin across entireti
studi in-lin pre-clin model drug figur
figur cell count trough baselin
therapi patient rheumatoid arthriti toni et al arthriti rheumat june volume pp
xencor seek partnership ige monoclon
develop atop condit includ allerg
rhiniti hay fever allerg conjunct pink eye atop dermat
eczema iv formul drug underw phase evalu
reformul subcutan deliveri updat phase result
last present novemb iv subcutan studi
show potenti reduc free ige level limit
quantit blq notabl atop patient treat weekli
subcutan dose achiev reduct free ige blq
day treatment
think key subcutan formul expect
move late stage studi think good strateg move
subcutan dose associ lower risk thrombocytopenia
would major concern subcutan dose could also easili
adopt clinic practic vs iv dose current seek
develop partner pharmacodynam model on-going
determin optim dose schedul
overal think degre ige inhibit could
compel rel current approv ige inhibitor omalizumab
xolair howev due risk thrombocytopenia emea
approv omalizumab patient sever asthma therefor
financi model market opportun limit
sever atop dermat ad indic may
lower safeti hurdl addit omzalizumab approv ad due
limit like associ inabl dose higher could help
limit competit biosimilar like enter market
current model gener million revenu
approv million attribut figur
figur forecast potenti gener million
moderate-sever atop atop dermat revenu patient sever inadequ control sever sever patient moder ad inadequ control moder moder patient number patient treat atop dermat revenu patient sever inadequ control sever sever patient moder ad inadequ control moder moder patient number patient treat
elev ige express associ type allerg condit
immunoglobulin ige one potent immunoglobulin
usual found within lung skin mucou typic present
lower concentr circul true role
ige bit elus elev allergen-specif express level
gener associ allerg condit includ clinic
condit xencor current pursu like chronic allerg rhiniti allerg
conjunct atop dermat
ige mediat inflamm allergen bind circul antigen
present cell apc travel lymph node activ resid
cell via receptor activ cell produc
cytokin figur releas cytokin serv
signal cell prolifer begin produc ige antibodi respond
foreign allergen bind allergen antigen bind arm
fab arm bind effector cell term crystalliz
arm fc arm fc arm gener activ effector cell bind
high affin receptor fcri lead synthesi subsequ
releas chemokin leukotrien addit cytokin
perpetu inflammatori respons
due high affin fcri receptor ige also bind
receptor absenc uncomplex antigen allergen fab
arm henc allergen bind respons rapid
figur ige elicit immun respons bind high affin receptor effector cell
sutton bj et al inhibit ige-receptor interact british medic bulletin
hannah gould rebecca beavil encyclopedia immunolog second edit
ration design promot rapid ige clearanc
design similar fab region xolair
modifi fc region bind lower affin fcrii receptor found
 cell figur enabl also sequest free ige
prevent ige bind cell promot rapid clearanc
antigen-antibodi complex sinc complex form
antigen antibodi complex undergo rapid clearanc un-complex
receptor easili clear
xolair omalizumab ige antibodi approv base
upon proven efficaci within allerg asthma slower clearanc
antigen antibodi complex antibodi sequest free serum ige
bind alloster site ige antigen use fab region also
prevent ige bind mast cell receptor directli bind high
affin fcri fc region howev bind omalizuamb fc
region fcri receptor effector cell creat antigen antibodi
complex plasma half-lif approxim week rel day
half-lif antibodi alon omalizumab dose everi week
uncomplex ige level increas remain elev
week drug discontinu clearanc rate omalizumab also known
slow patient higher baselin ige concentr receiv
rapid clearanc complex ige total ige level
treatment would true represent uninhibit
ige use guid alter treatment dose technic
challeng follow treatment omalizumab sinc post-treat ige
level skew complex ige inact still present
simpli slow attempt made
measur uncomplex free ige dissoci complex
step requir assay lead fals increas free ige level
clinic import low rang ng/ml
figur modifi fc domain allow potent inhibit rapid clearanc ige
compani report antibodi design
hamilton rg monitor allerg patient omalizumab free total serum ige measur allergi clin immunol pract
effect reduc total free ige
intraven dose
intraven dose studi first in-human data gener patient
allerg rhiniti allerg conjunct atop dermat baselin
total ige level iu/ml treat singl iv infus
efficaci intraven dose singl iv dose achiev rapid reduct
total ige level least day atop patient figur longer
treatment durat achiev within mg/kg mg/kg higher dose
cohort rapid reduct total ige level highli welcom sinc
current approv ige antibodi omalizumab show limit potenti
reduc total ige level due slower clearanc
impress reduct express fcri basophil
associ treatment view reduct express
fcri posit indic declin sinc uncomplex fcri
gener intern degrad reduct receptor express
reflect clinic respons even
figur singl iv dose result rapid complet reduct total free ige per day
foster et al random double-blind placebo-control ascend dose studi safeti toler
pharmacokinet
safeti profil iv dose iv dose appear toler
indic like hay fever pink eye eczema dose-depend reduct
platelet count observ patient receiv mg/kg
although reduct clinic signific patient treat
mg/kg develop mild moder thrombocytopenia
although incid thrombocytopenia transient case
recoveri week think risk thrombocytopenia could limit
optimist subcutan formul
deza et al basophil fc ri express chronic spontan urticaria potenti immunolog predictor respons omalizumab
subcutan dose
subcutan dose studi septemb phase studi
subcutan dose healthi volunt non-atop patient atop
patient initi half-lif drug dose subcutan
day similar iv dose patient dose weekli
week
efficaci subcutan dose novemb updat studi
provid promis efficaci observ non-atop patient
ige level declin limit quantit blq
maintain remaind treatment period least seven day
follow last dose subgroup atop subject high level
baselin free ige median ng/ml treatment four weekli subcutan
dose mg/kg show free ige level also
suppress blq figur approxim atop patient achiev
blq valu also maintain remaind treatment period
least seven day follow last dose free ige level
correl clinic efficaci data support
develop especi blq reduct ng/ml even
reduct less ng/ml known
figur weekli subcutan dose reduc total free ige
safeti subcutan dose subcutan dose appear
toler iv dose mild moder platelet count
decreas observ dose mg/kg weekli four week
approxim patient treat mg/kg platelet count
drop lower limit normal therefor think risk
thrombocytopenia albeit transient could potenti limit
efficaci seen lower dosag mg/kg safer dose
schedul could determin pharmacokinetic/pharmacodynam model
remain on-going determin optim dose schedul
carlsson et al variabl total free ige level ige receptor express allerg subject pollen season send
evlaut free ige patient achiev blq free ige patient achiev sustain blq free ige non-atop ng/ml median ng/ml median evalu total ige patient achiev blq total ige patient achiev sustain blq total ige non-atop iu/ml median iu/ml median ng/ml free ige iu/ml sustain blq indiat reduct maintain day dose
market opportun could signific
thrombocytopenia risk mitig optim dose schedul
efficaci profil encourag phase studi
intraven
subcutan dose proven antibodi effect
reduc ige level although atop patient dose
subcutan formul move forward clinic
develop think efficaci data appear competit reduct
free ige level atop patient treat limit quantit
could promis vs allerg rhiniti patient consid
symptom complet control although appl
appl comparison think free ige level post-treat similar
omalizumab patient baselin ige level iu/ml
offer insight figur lastli although weekli subcutan
dose could disadvantag rel omalizumab
everi two four-week dose think potenti use self-inject
similar one use dupix could allow adopt coupl
proven efficaci eas ige test
safeti dose although reduct platelet count
mild transient risk thrombocytopenia also one major
reason emea limit use omalizumab patient sever
asthma high risk mortal therefor view risk
thrombocytopenia concern await addit detail dose
optim howev posit view approv
omalizumab chronic spontan urticaria indic
physician like comfort despit advers event associ
figur dose frequent competit efficaci profil
casal tb et al anti-immunoglobulin omalizumab therapi season allerg rhiniti respir crit oct pt
omalizumabdupixenttargetig fcriib ige scheduleonc weeklyonc everi two week four weeksonc everi two weeksadministr routesubcutaneoussubcutaneoussubcutaneousfre ige reduct ng/ml -seriou aesthrombocytopenia shock herp conjunctitivi patient atop dermat allerg rhiniti allerg conjunct etc week week corren et al
conveni assay post-treat ige level approv
clinic trial gener version omalizumab think could
attempt off-label use indic like allerg rhiniti hay fever
allerg conjunct pink eye atop dermat eczema howev
cost test free ige level requir dose could
obtain payor approv test also slow patient reimburs
treatment therefor opportun could still exist efficaci
treatment requir standard cost-effect assay free ige
assay costli sinc may need outsourc
overal view potenti opportun atop dermat
although exact mix atop patient earli phase studi
disclos know proport patient atop
dermat meta-analysi mani small case seri support
continu evalu ige antibodi omalizumab treatment
meta-analysi result show clinic respons patient
lack respons patient said due use
subclin dose sinc patient ad tend higher ige level
patient allerg asthma indic omalizumab approv
therefor think optim dose patient could
promis think possibl sinc dose
frequent higher dose still effect clear unlik
omalizumab low clearanc rate higher drug concentr limit
potenti use clinic meaning dose think ad
indic safeti hurdl could accommod safeti profil
sinc omalizumab approv indic futur gener
competit could mitig current model includ
potenti partnership atop dermat indic
model gener million revenu
approv million attribut
ito et al develop assay determin free ige level serum patient treat omalizumab allergolog
wang hh et al efficaci omalizumab patient atop dermat systemat review meta-analysi allergi clin immunol
signific potenti bispecif oncolog pipelin
wide array preclin clinic solid liquid tumor
target bispecif antibodi retain us commerci right
use bi-specif promot t-cell recruit direct kill
tumor blast complet novel first bispecif approv us
came rate blincyto acut
lymphoblast leukemia addit sever bispecif antibodi
clinic mani view next gener target
think xencor long histori use well-establish numer
partner xmab platform antibodi develop allow
competit highlight on-going bispecif clinic
program also remain highli optimist much earlier bi-
figur deep bispecif oncolog pipelin
xencor bispecif antibodi one lead
immunotherapi drug candid develop
xencor engag t-cell arm aml blast
arm first clinic data program expect
base upon corollari clinic data macrogen
buy pt effort flotetuzumab gener optimist
outlook
acut myeloid leukemia aml one common form
leukemia affect peopl within aml character
accumul larg number cluster immatur non-
function blood cell commonli refer leukem blast within
blood bone marrow organ perturb normal
cytarabin chemotherapi regimen commonli
use treat aml patient respond well
therapi howev patient relaps due multipl reason
includ presenc leukem stem cell surviv standard
treatment regimen presenc novel clone inadequ
standard care treatment relaps refractori aml
prognosi gener poor although current treatment elicit
complet respons rate carri rate
treatment relat novel cytotox regimen target agent well
immunotherapi agent develop three
immunotherapi agent expect hold promis balanc
safeti efficaci profil express aml blast leukem
stem cell aml patient normal hematopoiet
excel marker direct t-cell kill
macrogen flotetuzumab phase shown promis efficaci signal
aml requir lead-in dose mitig cytokin releas
syndrom must dose continu rate
 antibodi high potenc also expect
associ toxic
safeti inde major concern sinc johnson johnson
phase studi place clinic hold
monospecif antibodi talacotuzumab trial aml also
termin recent sinc bind significantli lower
potenc safeti profil expect toler
also longer half-lif includ xtend domain data
phase dose expans cohort expect
signific focu toler continu dose-
escal think signific market opportun efficaci
therapi improv safeti conveni
statist acut myeloid leukemia cancer org
ehning et al distribut level cell surfac express acut myeloid leukemia blood cancer journal
ramo nr et al current approach treatment relaps refractori acut myeloid leukemia clin
novarti own ex-u right co-promot within us
market opportun model market-shar
flotetuzumab drug approv
commerci time-frame model drug class
achiev share refractory/ relaps aml popul
figur base upon current agreement novarti model
split revenu novarti within us equat
drug sale
figur model revenu follow split flotetuzumab
market sale estim sale estim sale attribut sale attribut xencortot sale attribut r/r case aml patient less patient achiev cr cr relaps patient penetr share share agent
xencor bispecif could potenti broad
use relaps refractori nhl cll set addit think
safeti allow use first-lin set could potenti increas
rate complet respons therefor limit number patient go
relaps first-in-human data expect
non-hodgkin lymphoma nhl affect peopl within
us chronic lymphocyt leukemia affect
approxim nhl cll case b-cell lymphoma
character abnorm differenti b-cell white blood cell
accumul within blood bone marrow cll lymph node
spleen nhl combin rituximab antibodi plu
chemotherapi commonli use first line nhl r-chop cll
although nhl patient achiev orr first line therapi
relaps similarli cll orr rate also high
patient achiev partial respons
relaps set nhl variou chemotherapi regimen combin
rituximab use addit transplant therapi subset
patient elig cll novel target therapi
prove benefici includ ibrutinib venetoclax patient fail
gener recommend transplant therapi ibrutinib larg limit
patient mutat venetoclax current limit
role well defin treatment landscap b-cell
malign surpris compet candid ahead
xencor regeneron neutral top-lin data present
 antibodi show
 patient remain studi major patient
discontinu due diseas progress format use
help limit occurr cytokin releas syndrom
also run risk limit effector function contrast
roch rate develop two promis
bispecif modifi fc domain ensur longer half-lif
construct evalu combin atezolizumab
nhl cll construct
evalu singl agent
seer non -hodgkin lymphoma nhl chronic lymphocyt leukemia cll
vo et al global region nation incid preval year live disabl diseas injuri
systemat analysi global burden diseas studi lancet oct
jain obrien initi treatment cll integr biolog function statu blood
caval fg hodgkin diseas treatment relaps diseas esmo
keat mj et al earli result chemoimmunotherapi regimen fludarabin cyclophosphamid rituximab initi therapi
stubenrauch et al impact molecular process hing region antibodi disposit profil
cynomolgu monkey drug metabol
ferl et al preclin popul pharmacokinet model t-cell-depend bispecif antibodi clin transl
think market could accommod multipl success
candid given larg opportun rituximab revenu north
billion howev could signific pressur differenti rel
bispecif well rituximab biosimilar expect hit market
earli see roch expertis antibodi develop
domin market major hurdl could room
anoth antibodi balanc safety-tox profil given
obinutuzumab pre-treat tociluzumab includ protocol
mitig treatment relat toxic novarti ex-u right
copromot within us
xencor incorpor known target low
high grade neuroendocrin gist tumor clinic relev
target cell promot tumor kill could allow better respons
rate overal surviv updat on-going phase dose escal
studi expect
neuroendocrin tumor net heterogen group usual
indol tumor aris neuroendocrin cell affect
peopl within tumor character
secret hormon peptid neuroendocrin cell lead multipl
symptom associ tumor growth gastrointestin net
frequent account net incid per
although tumor gener slow grow surviv rate
metastas surviv rate fall
surgeri cur treatment net option limit
highli local tumor complet resect
major patient elig cur surgeri palli care
commonli use limit symptom induc hormon secret earli
discoveri somatostatin receptor tumor lead develop
somatostatin analogu net sinc somatostatin known limit
hormon secret endocrin cell sever somatostatin
analogu use clinic practic today first approv
octreotid octreotid like approv analogu bind
somatostatin receptor express low grade
high grade gastrointestin net analogu effect reduc
symptom novel analogu allow conveni monthli dose
howev object tumor regress seldom occur symptom return
within year progress fee surviv rate remain poor
combin therapi everolimu mtor inhibitor
approv usual multipl signal pathway drive
everolimu octreotid intestin net show non-signific impact
vs signal known possibl escap mechan
express appear limit mostli well differenti high-
broder ms et al epidemiolog gastrointestin neuroendocrin tumor us commerci insur popul
grand hall dg gastrointestin stromal tumor neuroendocrin tumor semin oncol nur
pavel et al everolimu plu octreotid long-act repeat treatment advanc neuroendocrin tumour associ
grade even outcom patient well differenti
tumor treat pembrolizumab show orr
suggest also room improv
first patient phase dose escal studi dose
first look data expect phase
data help defin recommend phase dose pan-net
pnet gist net follow-on studi t-cell direct kill
strategi think safeti signific concern especi
determin use lower grade tumor program remain unpartn
antibodi preclin develop hold signific potenti valu
 ico bispecif antibodi includ well valid
target potenti highli efficaci
design use xencor robust xmab antibodi platform due highli
public natur target sever compet preclin
clinic candid pipelin includ
macrogen meru privat
contain modifi fc domain expect uniqu target
bind half-lif properti allow target cell kill limit
antibodi design undergon robust preclin
analysi earli data show select target cell
double-posit target toler bispecif primat
model said manag line typic seen
monospecif antibodi combin monospecif
antibodi thu requir micro dose despit preclin studi show
similar safeti profil line monospecif antibodi efficaci profil
differ case bispecif impact t-cell
activ combin mono-specif antibodi strategi
exampl xencor bispecif prove superior term
traffick cell tumor rel combin
also particularli impress preclin data
xencor present meet
show impress greater activ cell activ addit
checkpoint co-stim bi-specif ico significantli increas
activ cell rel monospecif antibodi alon
ind antibodi submit
expect dose ind
expect submit studi
initi earli
cavalcanti et al role express biomark gep neuroendocrin neoplasm grade cell death
partnership strateg collabor
robust natur xencor xmab antibodi platform afford xencor
opportun establish multipl licens agreement fc domain
well full antibodi construct think current partnership highlight
valu platform late stage clinic develop
partner candid attest qualiti candid develop
highlight partner clinic program includ alexion
rate paroxysm nocturn hemoglobinuria pnh atyp
hemolyt urem syndrom ahu well morphosi mor rate
chronic lymphocyt leukemia cll non-hodgkin
sign collabor licens agreement morphosi
develop commerci xencor phase candid
monospecif antibodi cytotox fc domain renam
morphosi advanc compound phase studi
patient non-hodgkin lymphoma nhl morphosi also receiv
breakthrough therapi design diffus larg b-cell
lymphoma dlbcl combin lenolidomid
car-t current approv dlbcl patient fail prior
chemotherapi regimen adopt stem cell therapi morphosi
believ could good altern option patient
frail undergo car-t cell therapi data lenolidomid
studi l-mind expect data support first
nda file approv within us subsequ approv
bendamustin line dlbcl also pursu
agreement elig receiv tier royalti percentag rang
high single-digit low-doubl digit net sale commerci product
current model approv line dlbcl revenu
approxim attribut xencor
figur estim may conserv addit label indic
like posit outlook potenti establish
franchis drug candid one reason morphosi
establish adr program april
figur current model approv line dlbcl
enter collabor licens agreement
novarti co-develop bi-specif antibodi
allow novarti receiv ex-u commerci right candid
low double-digit royalti term agreement
novarti also receiv world-wid right xencor bi-specif domain
develop four addit candid one opt co-
develop co-commerci within us novarti also gain non-
exclus licens xmab platform develop drug candid
receiv million up-front elig receiv billion
also on-going option licens agreement alexion
enter agreement allow alexion util
xencor xtend domain increas half-lif antibodi six
drug program technolog use alexion success develop
long-act antibodi defens strategi new biosimilar
entrant current market antibodi solari similar
solari alexion plan seek approv paroxysm nocturn
hemoglobinuria pnh atyp hemolyt urem syndrom ahu
indic solari sale exceed annual
current agreement remain elig receiv undisclos
amount regulatori mileston payment pend nda submiss
approv receiv low-singl digit royalti net
revenu total revenu us revenu revenu estim revenu attributat diffus larg b-cell lymphoma dlbcl dlbcl revenu line treatment patient relaps line relaps refractori dlbcl revenu line treatment patient line relaps line relaps refractori
sale base consensu revenu estim sale project
revenu would expect
receiv net royalti revenu figur importantli think
success develop date phase pivot studi
showcas capabl xmab antibodi platform data
expect
figur model approv pnh ahu sale
xencor boehring ingelheim enter research option
agreement allow boehring util xencor cytotox fc domain
boehring develop two phase candid use fc domain
two drug candid antibodi chronic lymphocyt
leukemia cll antibodi acut myeloid leukemia
aml myeloid dysplast syndrom md agreement end
defer revenu compound remain
develop royalti payment associ commerci
drug candid disclos neither drug candid
model await updat manag
revenu total revenu total revenu us revenu revenu estim revenu attribut nocturan hemoglobinuria pnh revenu patient pnh revenu patient hemolyt urem syndrom ahu revenu patient ahu revenu patient treated-
xencor antibodi platform allow design human mono-
specif bi-specif antibodi modifi fc domain allow
tailor half-lif degre cytotox immun effector activ
figur structur domain allow plug play function
retain potenti manufactur use standard process
inhibitor domain specif design promot rapid clearanc
antibodi bind antigen ensur quick reduct pro-
tailor antibody-depend cellular cytox sinc modifi fc
domain lead activ natur killer cell strongli desir
sinc adcc function known key efficaci mani approv
half-lif antibodi day week allow less
frequent antibodi dose domain use next gen blincyto
develop rate
enabl dual antigen target maintain rather stabl structur
addit modif domain allow easier purif
manufactur antibodi
xencor xmab platform sever antibodi domain support
success develop multipl clinic target
partner xencor pipelin includ sever preclin clinic candid
incorpor variou domain xmab platform well
combin domain exampl checkpoint bi-specif inhibitor
util bispecif xtend domain highlight plug
play natur platform
howev compet antibodi platform avail
key competit one figur platform
posit neg aspect relat clinic develop
exampl bite platform use develop blincyto known
antibodi high permeabl due small size also result
shorter half-lif less conveni dose schedul similarli genmab
rate duobodi platform creat fulli human antibodi
therefor think addit robust platform target
select must ideal indic even import bi-
specif target must work synergist multipl on-going studi
across industri manag also incorpor learn
limit current clinic compound gener optimist
xencor pipelin includ well valid target
figur comparison xencor xmab platform competit antibodi platform
bispecif antibodi develop tumor immunotherapi februari dart trident lead multi-specif antibodi
platformcompanystructureprosconsxmabxencorigg scfvadcc activ limit mismatch standard manufacturingno ci bind modal biteamgenscfv-basedgood permeabl limit mismatchshort half-lif diffult purifi low affinityduobodygenmabig-likehuman like good pharmacokinet complex manufacturingcrossmabrocheig-likeful length antibodi high affin contain fc regiondifficult purifydartmacrogenicsdiabodyfc non-fc antibodi capabl high stabilityshort half-lif non-fc antibodi low permeabl fc antibodi
xencor manag team strong scientif clinic background
platform cso dr desjarlai expand compani
technolog develop clinic effort facilit dr foster
intern medicin haematologist/oncologist held similar role
compani like biogen idec abbott busi develop effort
led dr baracchini record facilit
negoti john kuch serv cfo firm
figur xencor strong execut manag team
clinical-stag compani develop monospecif bispecif
antibodi use autoimmun diseas allerg diseas certain
cancer figur compani reli xmab anti-bodi platform
design fc modifi antibodi uniqu profil ensur improv clinic
activ rel competitor compani found around
drug discoveri platform co-develop current ceo dr bassil
compani enter public market base monrovia
figur xencor clinic pipelin continu expand sever activ recruit studi
bioavail studycompletedphas evalu effect diseas activ patient diseas rd completedphas studi effect patient system lupu erythematosusact recruitingphas toler adult volunt adult subject histori allerg rhiniti and/or allerg conjunct and/or atop dermatitiscompletedphas toler bioavail subcutan administ studi evalu safeti toler patient hematolog malignanciesrecruitingphas evalu safeti toler patient hematolog malignanciesrecruitingphas studi subject net gistrecruitingphas studi subject select advanc solid tumorsrecruitingphas
risk rate recommend
buy rate price target may prove inaccur due number
risk relat earli stage biotech compani
current revenu
posit data approv model drug candid
guarante may occur within current timelin us
fda european approv guarante compani
may need run addit studi current contempl
within clinic develop timelin
market penetr rate drug candid could less
anticip variou reason includ reimburs safeti
compani reli outsid sourc capit event
capit avail could ceas oper
incom collabor good margin market develop administr administr margin incom expens gain loss share share ep growth yoy
btig cover compani mention report
appendix analyst certif import disclosur
